BioStock: Iconovo address maternal health in partnership with Monash University

In a final push before the Christmas break this week, the inhalation device company Iconovo announced the signing of a deal with Monash University to develop an inhaled oxytocin treatment against postpartum haemorrhage using Iconovo’s ICOone platform. The project is supported by a research agreement with Johnson & Johnson aimed at speeding up clinical development. BioStock takes a closer look at the ramifications of this new partnership. 

Read the full article at biostock.se:

https://www.biostock.se/en/iconovo-address-maternal-health-in-partnership-with-monash-university/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se